Drugs & Targets FDA approves encorafenib with binimetinib for metastatic NSCLC with a BRAF V600E mutation October 13, 2023Vol.49 No.38
Drugs & Targets Shasqi, Johnson & Johnson expand existing research collaboration October 13, 2023Vol.49 No.38
Drugs & Targets Delfi Diagnostics commercializes blood test for lung cancer screening October 13, 2023Vol.49 No.38
Drugs & Targets FDA grants first marketing authorization for DNA test to assess predisposition for dozens of cancer types October 06, 2023Vol.49 No.37
Drugs & Targets FDA grants priority review to odronextamab for R/R follicular lymphoma and R/R diffuse large B-cell lymphoma October 06, 2023Vol.49 No.37
Drugs & Targets FDA proposes rule aimed at ensuring safety and effectiveness of laboratory developed tests October 06, 2023Vol.49 No.37
Drugs & Targets FDA establishes pilot program to accelerate development of rare disease therapies October 06, 2023Vol.49 No.37
Drugs & Targets FDA clears automated assay to assess tumor progression in neuroendocrine cancer September 29, 2023Vol.49 No.36
Drugs & Targets Mythic Therapeutics receives FDA Fast Track designation for MYTX-011 in NSCLC with cMET overexpression September 29, 2023Vol.49 No.36
